183 related articles for article (PubMed ID: 19021070)
1. Complete remission and virologic response to combined chemoimmunotherapy (R-CVP) followed by rituximab maintenance in HIV-negative, HHV-8 positive patient with multicentric Castleman disease.
Fragasso A; Mannarella C; Ciancio A; Calvario A; Scarasciulli ML
Leuk Lymphoma; 2008 Nov; 49(11):2224-6. PubMed ID: 19021070
[No Abstract] [Full Text] [Related]
2. Complete remission in a pancytopenic HIV negative, HHV-8 positive patient with multicentric Castleman's disease induced with anti-CD20.
Cervera Grau JM; Galiana Esquerdo G; Llorca Ferrándiz C; Briceño García H; Díaz Castellano M; Férriz Moreno P
Clin Transl Oncol; 2006 Jul; 8(7):540-1. PubMed ID: 16870545
[TBL] [Abstract][Full Text] [Related]
3. HIV-associated multicentric Castleman disease.
Oksenhendler E
Curr Opin HIV AIDS; 2009 Jan; 4(1):16-21. PubMed ID: 19343828
[TBL] [Abstract][Full Text] [Related]
4. Development of Kaposi's sarcoma after complete remission of multicentric Castlemans disease with rituximab therapy in a HHV8-positive, HIV-negative patient.
Law AB; Ryan G; Lade S; Prince HM
Int J Hematol; 2010 Mar; 91(2):347-8; author reply 349. PubMed ID: 20146033
[No Abstract] [Full Text] [Related]
5. Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease.
Powles T; Stebbing J; Montoto S; Nelson M; Gazzard B; Orkin C; Webb A; Bower M
Blood; 2007 Dec; 110(12):4132-3. PubMed ID: 18024800
[No Abstract] [Full Text] [Related]
6. Complete remission in 4 patients with human herpesvirus 8-associated multicentric Castleman disease using rituximab and liposomal doxorubicin, a novel chemotherapy combination.
Peker D; Martinez AE; Schwartz MA; Cusnir M
Clin Adv Hematol Oncol; 2012 Mar; 10(3):204-6. PubMed ID: 22402431
[No Abstract] [Full Text] [Related]
7. Brief communication: rituximab in HIV-associated multicentric Castleman disease.
Bower M; Powles T; Williams S; Davis TN; Atkins M; Montoto S; Orkin C; Webb A; Fisher M; Nelson M; Gazzard B; Stebbing J; Kelleher P
Ann Intern Med; 2007 Dec; 147(12):836-9. PubMed ID: 18087054
[TBL] [Abstract][Full Text] [Related]
8. HHV8-positive, HIV-negative multicentric Castleman's disease: early and sustained complete remission with rituximab therapy without reactivation of Kaposi sarcoma.
Nicoli P; Familiari U; Bosa M; Allice T; Mete F; Morotti A; Cilloni D; Saglio G; Guerrasio A
Int J Hematol; 2009 Oct; 90(3):392-396. PubMed ID: 19756920
[TBL] [Abstract][Full Text] [Related]
9. Rituximab therapy for HIV-associated Castleman disease.
Marcelin AG; Aaron L; Mateus C; Gyan E; Gorin I; Viard JP; Calvez V; Dupin N
Blood; 2003 Oct; 102(8):2786-8. PubMed ID: 12842986
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of iatrogenic multicentric Castleman's disease arising due to recrudescence of HHV-8 in a liver transplant patient.
Speicher DJ; Sehu MM; Mollee P; Shen L; Johnson NW; Faoagali JL
Am J Transplant; 2014 May; 14(5):1207-13. PubMed ID: 24674650
[TBL] [Abstract][Full Text] [Related]
11. Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy.
Corbellino M; Bestetti G; Scalamogna C; Calattini S; Galazzi M; Meroni L; Manganaro D; Fasan M; Moroni M; Galli M; Parravicini C
Blood; 2001 Dec; 98(12):3473-5. PubMed ID: 11719390
[TBL] [Abstract][Full Text] [Related]
12. EBV+ HHV-8+ Multicentric Castleman Disease With Plasmablastic Aggregates in an HIV+ Man: An Evolving Clinicopathologic Entity.
Shivane A; Pearce A; Khatib N; Smith MEF
Int J Surg Pathol; 2018 Jun; 26(4):338-341. PubMed ID: 29198143
[TBL] [Abstract][Full Text] [Related]
13. The management of Castleman disease.
Lomas OC; Streetly M; Pratt G; Cavet J; Royston D; Schey S; Ramasamy K;
Br J Haematol; 2021 Nov; 195(3):328-337. PubMed ID: 34340261
[No Abstract] [Full Text] [Related]
14. How I treat HHV8/KSHV-related diseases in posttransplant patients.
Riva G; Luppi M; Barozzi P; Forghieri F; Potenza L
Blood; 2012 Nov; 120(20):4150-9. PubMed ID: 22968461
[TBL] [Abstract][Full Text] [Related]
15. Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease.
Bower M; Veraitch O; Szydlo R; Charles P; Kelleher P; Gazzard B; Nelson M; Stebbing J
Blood; 2009 May; 113(19):4521-4. PubMed ID: 19224759
[TBL] [Abstract][Full Text] [Related]
16. Human immunodeficiency virus-associated multicentric Castleman disease refractory to antiretroviral therapy: clinical features, treatment and outcome.
Alzahrani M; Hull MC; Sherlock C; Griswold D; Leger CS; Leitch HA
Leuk Lymphoma; 2015 May; 56(5):1246-51. PubMed ID: 25093377
[TBL] [Abstract][Full Text] [Related]
17. Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease.
Uldrick TS; Polizzotto MN; Aleman K; Wyvill KM; Marshall V; Whitby D; Wang V; Pittaluga S; O'Mahony D; Steinberg SM; Little RF; Yarchoan R
Blood; 2014 Dec; 124(24):3544-52. PubMed ID: 25331113
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of multicentric Castleman's disease with bilateral orbital tumour using rituximab.
Ide M; Ogawa E; Kasagi K; Kawachi Y; Ogino T
Br J Haematol; 2003 Jun; 121(5):818-9. PubMed ID: 12780800
[No Abstract] [Full Text] [Related]
19. Human Herpesvirus Type 8-positive Multicentric Castleman Disease.
Melikyan AL; Egorova EK; Julhakyan HL; Kovrigina AL; Savchenko VG
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S159-65. PubMed ID: 27133959
[TBL] [Abstract][Full Text] [Related]
20. Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment.
Casper C; Nichols WG; Huang ML; Corey L; Wald A
Blood; 2004 Mar; 103(5):1632-4. PubMed ID: 14615380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
